Positron Emission Tomography Imaging of Prostate Cancer with Ga-68-Labeled Gastrin-Releasing Peptide Receptor Agonist BBN$_{7-14}$ and Antagonist RM26

Siyuan Cheng, Lixin Lang, Zhantong Wang, Orit Jacobson, Bryant Yung, Guizhi Zhu, Dongyu Gu, Ying Ma, Xiaohua Zhu, Gang Niu, and Xiaoyuan Chen

$^1$Department of Nuclear Medicine and PET, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, PR China

$^2$Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, Maryland 20892, United States

ABSTRACT: Radiolabeled bombesin (BBN) analogs have long been used for developing gastrin-releasing peptide receptor (GRPR) targeted imaging probes, and tracers with excellent in vivo performance including high tumor uptake, high contrast, and favorable pharmacokinetics are highly desired. In this study, we compared the $^{68}$Ga-labeled GRPR agonist (Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH$_2$, BBN$_{7-14}$) and antagonist (D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH$_2$, RM26) for the positron emission tomography (PET) imaging of prostate cancer. In the in vitro stabilities, receptor binding, cell uptake, internalization, and efflux properties of the probes $^{68}$Ga-(1,4,7-triazacyclonane-1,4,7-triacetic acid (NOTA))-Aca-BBN$_{7-14}$ and $^{68}$Ga-NOTA-poly(ethylene glycol), (PEG)$_3$-RM26 were studied in PC-3 cells, and the in vivo GRPR targeting abilities and kinetics were investigated using PC-3 tumor xenografted mice. BBN$_{7-14}$-PEG$_3$-RM26, NOTA-Aca-BBN$_{7-14}$ and NOTA-PEG$_3$-RM26 showed similar binding affinity to GRPR. In PC-3 tumor-bearing mice, the tumor uptake of $^{68}$Ga-NOTA-PEG$_3$-RM26 remained at around 3.00 percentage of injected dose per gram of tissue within 1 h after injection, in contrast with $^{68}$Ga-NOTA-Aca-BBN$_{7-14}$, which demonstrated rapid elimination and high background signal. Additionally, the majority of the $^{68}$Ga-NOTA-Aca-BBN$_{7-14}$ was degraded under the same conditions, demonstrating more-favorable in vivo pharmacokinetic properties and metabolic stabilities of the antagonist probe relative to its agonist counterpart. Overall, the antagonist GRPR targeted probe $^{68}$Ga-NOTA-PEG$_3$-RM26 is a more-promising candidate than the agonist $^{68}$Ga-NOTA-Aca-BBN$_{7-14}$ for the PET imaging of prostate cancer patients.

INTRODUCTION

Prostate cancer (PCa) accounts for almost 20% of the newly diagnosed cancers among men in the United States in 2017 and remains the third-leading cause of cancer related male death.\(^1\) A typical diagnosis of PCa relies on the histopathological examination of suspected prostate biopsy tissues or specimens from benign prostatic enlargement surgeries or transurethral resection of the prostate following the detection of elevated prostate-specific antigen (PSA) levels, abnormal digital rectal examination (DRE), bone scanning, or a combination of all three. X-ray computed tomography and magnetic resonance imaging (MRI) are currently the major imaging techniques for further identification of PCa.\(^2\) However, the capacity of conventional diagnostic techniques for primary lesion detection, staging, or relapse monitoring of PCa is limited.\(^3\) For example, the PSA test can be interfered by noncancerous factors such as prostate enlargement, old age, and prostatitis, and low levels of PSA do not necessarily rule out the incidence of PCa.\(^4\) The sensitivity and specificity of either ultrasound or MRI is also limited by abnormal signals confounded by prostatitis or benign prostatic hyperplasia (BPH).\(^5,6\) The notable multiparametric MRI (MP-MRI) remains imperfect as well, with a pooled sensitivity of up to 89% and a specificity of up to 73%.\(^7\)

Interest in applying molecular imaging to positron emission tomography (PET) has grown, and a plethora of radiotracers have been developed and investigated actively for PCa. The classical 2-deoxy-2-$^{18}$F-fluoro-D-glucose ($^{18}$F-FDG) has been used for evaluating late-stage or recurrent PCa but is not particularly avid.\(^8,9\) Other promising agents targeting metabo-
lites such as fatty acids and amino acids (e.g., $^{13}$C- and $^{18}$F-choline, $^{13}$C-acetate, and $^{18}$F-FACBC) have been further introduced$^{3,10}$ as well as agents targeting specific PCA antigens such as prostate-specific membrane antigen (PSMA).$^{11,12}$ These tracers are proven beneficial for recurrent PC diagnosis and staging. The PSMA targeted tracers have also been specifically applied for predicting the optimal timing of PSMA-based therapies.$^{13}$ However, almost all these tracers show limited diagnostic accuracy for primary lesions,$^{3,10,14}$ and few of those tracers have been sufficiently investigated and clinically validated to date.

The gastrin-releasing peptide receptor (GRPR) is a G protein-coupled receptor expressed in various organs of mammals, especially in the gastrointestinal tract and the pancreas. Upon binding with the ligand gastrin-releasing peptide (GRP), GRPR can be activated and elicit certain physiological processes.$^{15}$ Notably, GRPR over-expression is related to the exocrine or endocrine secretions to regulate multiple peptide (GRP), GRPR can be activated and elicit certain physiological processes.$^{15}$ Notably, GRPR over-expression is presented in several types of tumors such as prostate, urinary tract, gastrointestinal stromal, breast, and lung and is related to proliferation and growth of these malignancies.$^{16,17}$ Especially, GRPR is almost 100% expressed in clinical PCa samples.$^{18,19}$ For example, the GRPR agonist BBN$^{7}$ as an amphibian homologue of GRP, bombesin (BBN) was found to bind to GRPR with a high affinity. For decades, the BBN motifs have been used extensively in radioactive imaging or in radiopharmaceutical therapy for over-expressing cancers.$^{18,19}$ For example, the GRPR agonist BBN$^{14}$ and a truncated form of BBN with the sequence of Gln−Trp−Ala−Val−Gly−His−Leu−Met−NH$_2$ has been studied as PET or single photon emission computed tomography (SPECT) tracers in both preclinical and clinical research.$^{20}$ In the meantime, numerous clinical trials have been performed using antagonistic GRPR targeting PET radiopharmaceuticals including $^{68}$Ga−RM2,$^{21}$ $^{68}$Ga−SB3,$^{22}$ $^{68}$Ga−BAY86−7458, and $^{68}$Ga−CB−TE2A−AR06.$^{23}$ Recently, a nine-amino-acid analog of nonapeptide BBN$^{6,14}$−$^{14}$ in saline and FBS (Figure 2). After 2 h of incubation, the radiochemical yield was $>$90−95% and radiochemical purity was $>$98%. The chemical structures of $^{68}$Ga−NOTA−Aca−BBN$^{14}$ and $^{68}$Ga−NOTA−PEG$_1$−RM2 were presented in Figure 1.

**RESULTS**

**Synthesis and Radiolabeling.** With excess amounts of 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA)−N-hydroxysuccinimide (NHS), the NOTA−Aca−BBN$_{7−14}$ and NOTA−poly(ethylene glycol)$_3$−PEG$_1$−RM2 conjugate were produced in $>$95% yield. A m/z of 1338 for [M + H$^+$] was identified for NOTA−Aca−BBN$_{7−14}$ using matrix-assisted laser desorption ionization−time-of-flight mass spectrometry (MALDI−TOF MS). NOTA−PEG$_1$−RM2 was synthesized and characterized by the same method (m/z = 1601 for [M + H$^+$]). Both conjugates were labeled with $^{68}$Ga within 20 min, with specific activities of 21.6−40.01 and 26.7−53.33 MBq/nmol, respectively, for $^{68}$Ga−NOTA−Aca−BBN$_{7−14}$ and $^{68}$Ga−NOTA−PEG$_1$−RM2, and for both, radiochemical yield was $>$90−95% and radiochemical purity was $>$98%. The chemical structures of $^{68}$Ga−NOTA−Aca−BBN$_{7−14}$ and $^{68}$Ga−NOTA−PEG$_1$−RM2 were presented in Figure 1.

**In Vitro Stability.** In vitro stabilities of $^{68}$Ga−NOTA−Aca−BBN$_{7−14}$ and $^{68}$Ga−NOTA−PEG$_1$−RM2 in saline and nonheat-inactivated fetal bovine serum (FBS) (Gibco) were determined according to peak integration of analytical high-performance liquid chromatography (HPLC). At 0 min of the incubation, the radiochemical purities of $^{68}$Ga−NOTA−Aca−BBN$_{7−14}$ and $^{68}$Ga−NOTA−PEG$_1$−RM2 were all $>$95% in both saline and FBS (Figure 2). After 2 h of incubation, the parent compound of $^{68}$Ga−NOTA−Aca−BBN$_{7−14}$ in saline dropped to 88.42% along with a more-hydrophilic peak of 11.58%, while this metabolism for $^{68}$Ga−NOTA−Aca−BBN$_{7−14}$ incubated in FBS was not as obvious. Metabolites represented by radio peaks of slightly higher lipophilicity than the parent compounds were observed for both after 2 h incubation in FBS, accompanied by the percentages of the parent compounds dropping to 89.24% and 80.58%, respectively. For $^{68}$Ga−NOTA−PEG$_1$−RM2, the parent compound dropped to 88.42% along with a more-hydrophilic peak of 11.58%, while this metabolism for $^{68}$Ga−NOTA−PEG$_1$−RM2 incubated in FBS was not as obvious. Metabolites represented by radio peaks of slightly higher lipophilicity than the parent compounds were observed for both after 2 h incubation in FBS, accompanied by the percentages of the parent compounds dropping to 89.24% and 80.58%,
respectively, for $^{68}$Ga–NOTA–Aca–BBN$_{7-14}$ and $^{68}$Ga–NOTA–PEG$_3$–RM26.

**Competitive Binding Assay.** The GRPR-binding affinities of BBN$_{7-14}$, PEG$_3$–RM26, NOTA–Aca–BBN$_{7-14}$, and NOTA–PEG$_3$–RM26 were assessed by competitive binding assay using $^{125}$I–[Tyr$^4$]BBN as the radioligand. The results of these assays were shown in Figure 3. The binding of $^{125}$I–[Tyr$^4$]BBN to GRPR was displaced by the cold analogs in a concentration-dependent manner. The half maximal inhibitory concentration (IC$_{50}$) values of BBN$_{7-14}$, PEG$_3$–RM26, NOTA–Aca–BBN$_{7-14}$, and NOTA–PEG$_3$–RM26 were 0.32 ± 0.10, 0.41 ± 0.13, 1.80 ± 0.67, and 2.05 ± 0.50 nM, respectively. The results indicated that the intermolecular targeting abilities of BBN$_{7-14}$ and PEG$_3$–RM26 for GRPR were comparable. After the NOTA conjugation, the affinities of both compounds decreased to some extent. However, there were no distinct disparities discovered between NOTA–Aca–BBN$_{7-14}$ and NOTA–PEG$_3$–RM26, either.

**Cell Uptake, Internalization, and Efflux.** A time-dependent cellular-uptake pattern in GRPR positive PC-3 cells was observed for both $^{68}$Ga–NOTA–Aca–BBN$_{7-14}$ and $^{68}$Ga–NOTA–PEG$_3$–RM26. The uptake of $^{68}$Ga–NOTA–Aca–BBN$_{7-14}$ increased rapidly to nearly 27% within 1 h of incubation, and that of $^{68}$Ga–NOTA–PEG$_3$–RM26 was slightly lower (Figure 4A). The agonist $^{68}$Ga–NOTA–Aca–BBN$_{7-14}$ showed distinctively high internalization, and around 74% of the radioactivity uptake was internalized within 1 h of incubation. In contrast, $^{68}$Ga–NOTA–PEG$_3$–RM26 showed very low internalization (<15% of total uptake; Figure 4A). After washing and medium replacement, both of the tracers showed efflux with a similar pattern (Figure 4B). At 60 min, 50% of radioactivity uptake was still retained with the cells.

**In Vivo PET Imaging.** Representative coronal PET images of PC-3 tumor-bearing mice at different time points are shown in Figure 5. The tumors were clearly visualized with high contrast at all the time points for $^{68}$Ga–NOTA–PEG$_3$–RM26 ($n = 3$) as well as at 15 and 30 min for $^{68}$Ga–NOTA–Aca–BBN$_{7-14}$ ($n = 4$). However, at 60 min post-injection, the tumor became much less visible in the mice administered with $^{68}$Ga–NOTA–Aca–BBN$_{7-14}$ (Figure 5A). Meanwhile, both of the
tracers showed considerable accumulation and retention in the abdominal regions including pancreas and intestines, although less was observed for $^{68}$Ga–NOTA–PEG$_3$–RM26 than for $^{68}$Ga–NOTA–Aca–BBN$_{7-14}$. At these early time points, relatively high kidney radioactivity was observed while the radioactivity in the bladder was constantly high for these two probes, suggesting that the tracers were excreted mainly by the renal system.

Activity accumulation in the tumor was quantified by measuring the regions of interest (ROIs) on the coronal images (Figure 5B,C). The mean tumor uptake was determined to be $4.40 \pm 0.29$, $3.28 \pm 0.47$, and $2.04 \pm 0.34$ percentage of injected dose per gram of tissue (%ID/g) for $^{68}$Ga–NOTA–Aca–BBN$_{7-14}$ and $^{68}$Ga–NOTA–PEG$_3$–RM26 at 15, 30, and 60 min, respectively, when comparing tumor uptake of the two tracers at the same time points post-injection.

However, the maximum tumor uptake was determined to be $6.68 \pm 0.69$, $5.14 \pm 1.15$, and $4.77 \pm 0.96$%ID/g for $^{68}$Ga–NOTA–Aca–BBN$_{7-14}$ and $^{68}$Ga–NOTA–PEG$_3$–RM26 at 15, 30, and 60 min, with the corresponding $P$ values of <0.01, 0.39, and 0.02, respectively, when comparing tumor uptake of the two tracers at the same time points post-injection.

**Biodistribution of $^{68}$Ga–NOTA–Aca–BBN$_{7-14}$ and $^{68}$Ga–NOTA–PEG$_3$–RM26.** The biodistribution of $^{68}$Ga–NOTA–Aca–BBN$_{7-14}$ ($n = 4$) and $^{68}$Ga–NOTA–PEG$_3$–RM26 ($n = 3$) in tumor and normal tissues determined by $\gamma$-counting was presented in Figure 6A. In good agreement with the PET images, high uptake and long retention of the radioactivity were observed for the GRPR-positive tissues including pancreas, intestine, and PC-3 tumor at 60 min post-injection, which were $17.99 \pm 1.48$, $4.33 \pm 1.90$, and $2.40 \pm 0.38$%ID/g for $^{68}$Ga–NOTA–Aca–BBN$_{7-14}$ and $9.51 \pm 0.73$, $0.92 \pm 0.12$, and $3.31 \pm 0.68$%ID/g for $^{68}$Ga–NOTA–PEG$_3$–RM26.

However, the tumor-to-lung, tumor-to-liver, tumor-to-kidney, tumor-to-pancreas, tumor-to-intestine, and tumor-to-muscle ratios for the radiopharmaceuticals at 1 h post-injection were shown in Figure 6B, which were $2.66, 9.66, 3.22, 0.34, 3.69$, and $72.5$ for $^{68}$Ga–NOTA–PEG$_3$–RM26 and $5.34, 3.15, 1.52, 0.13, 0.56$, and $25.57$ for $^{68}$Ga–NOTA–Aca–BBN$_{7-14}$, respectively. Except for the tumor-to-lung uptake ratios, $^{68}$Ga–NOTA–PEG$_3$–RM26 showed much better tumor-to-organ contrast than that of $^{68}$Ga–NOTA–Aca–BBN$_{7-14}$ ($P$ values of <0.01 and <0.05). Specially, the tumor-to-muscle ratio of...
BBN analogues have been widely labeled with radionuclides such as $^{68}$Ga, $^{64}$Cu, $^{18}$F, and $^{177}$Lu. In particular, $^{68}$Ga can be easily produced due to the availability and commercialization of the in-house $^{68}$Ge and $^{68}$Ga generators ($^{68}$Ge, $t_{1/2}$ = 270.8 days). The $^{68}$Ga-labeling of BBN derivatives conjugates come with high labeling yield, satisfactory radiochemical purity, and specific activity, and the clinical implementation of $^{68}$Ga radiopharmaceuticals is preferred in the routine clinical setup of nuclear medicine. In this study, both BBN-based probes were prepared with high radiochemical purity and specific activity within 20 min, demonstrating ideal radiochemical processing for clinical translation.

In this study, we synthesized the NOTA-conjugated GRPR agonist BBN$_{14}$ and antagonist RM26; PEG$_3$ was used as a linker to conjugate NOTA to the antagonist peptide. The IC$_{50}$ values of NOTA–Aca–BBN$_{14}$ and NOTA–PEG$_3$–RM26 were similar to each other and also close to analogs reported from other laboratories previously.

Despite similar binding affinities, the tumor uptake of $^{68}$Ga–NOTA–Aca–BBN$_{14}$ dropped rapidly from 4.40%ID/g at 15 min to 2.04%ID/g at 60 min post-injection in our study, and that of $^{68}$Ga–NOTA–PEG$_3$–RM26 remained at a plateau of around 3.00%ID/g. The declining pattern of tumor uptake for $^{68}$Cu–NOTA–Aca–BBN$_{14}$ in PC-3 tumor mice from 1 to 24 h post-injection has also been reported previously, and the authors speculate that the signal decrease was primarily due to rapid clearance from the bloodstream and excretion via the renal-urinary pathway. Both $^{68}$Ga–NOTA–Aca–BBN$_{14}$ and $^{68}$Ga–NOTA–PEG$_3$–RM26 were mainly excreted through the urinary tract, so high accumulation of radioactivity in the bladder was observed. However, the kidney uptake was moderate compared with other peptide-based tracers. Consistently, we observed most of $^{68}$Ga–NOTA–PEG$_3$–RM26 in serum remained intact at 5 min after injection, in comparison to 3.16% of $^{68}$Ga–NOTA–Aca–BBN$_{14}$, indicating much greater metabolic stability in vivo for the antagonist and better suitability for GRPR imaging of $^{68}$Ga–NOTA–PEG$_3$–RM26.

In agreement with the PET imaging study, the ex vivo biodistribution results further validated higher tumor-to-organ ratios for $^{68}$Ga–NOTA–PEG$_3$–RM26 in comparison with those of $^{68}$Ga–NOTA–Aca–BBN$_{14}$ at 60 min after injection. Hence, the higher tumor uptake and lower background offer $^{68}$Ga–NOTA–PEG$_3$–RM26 more sensitivity in detecting indistinct lesions, such as metastasis distributed in the abdominal area in clinical settings.

It is well-known that introduction of different linkers between the metal chelator and targeting peptide sequence results in different tumor uptake and distinct normal organ distribution. Indeed, we have included $^{68}$Ga–NOTA–PEG$_3$–Aca–BBN$_{14}$ in the experimental design for this comparison study. However, both PET imaging and biodistribution results revealed that $^{68}$Ga–NOTA–PEG$_3$–Aca–BBN$_{14}$ was the worst probe compared with the other two probes. The results indicated that the PEG modification itself did not substantially alter the in vivo pharmacokinetics of BBN$_{14}$, and the difference between $^{68}$Ga–NOTA–Aca–BBN$_{14}$ and $^{68}$Ga–NOTA–PEG$_3$–RM26 mainly came from the inherent distinction of the peptide sequences and the agonism and antagonism of the two probes.

For in vitro stability assay, a minor portion of relatively hydrophilic radio peak was observed for $^{68}$Ga–NOTA–Aca–
BBN\textsubscript{7-14} incubated in saline, which could result from radiolysis of the Met residue of \textsuperscript{68}Ga−NOTA−Aca−BBN\textsubscript{7-14} while in FBS incubation, this kind of decomposition was possibly suppressed by the presence of serum proteins.\textsuperscript{41,42} Moreover, a slightly more lipophilic radio peak was observed after 120 min incubation in nonheat inactivated FBS for both \textsuperscript{68}Ga−NOTA−Aca−BBN\textsubscript{7-14} and \textsuperscript{68}Ga−NOTA−PEG\textsubscript{3}−RM26, each consisting 10.76\% and 19.42\% of the radiopharmaceuticals. Formation of these metabolites may have been derived from the action of serum proteases in nonheat inactivated FBS such as carboxamidase, which could catalyze the hydrolysis of C-terminal carboxamides to the corresponding carboxy acid.\textsuperscript{43}

In vivo stability assay via radio-HPLC also indicated better stability of \textsuperscript{68}Ga−NOTA−Aca−BBN\textsubscript{7-14} compared to \textsuperscript{68}Ga−NOTA−Aca−BBN\textsubscript{7-14} in tumor homogenates. However, the structure of the radioactive fragments was not identified because the mass amount for the injection was limited. In a previous study, we observed a rapid degradation of BBN\textsubscript{7-14} during incubation in rat hepatocytes ($t_{1/2} = 4$ min), and the metabolites of BBN\textsubscript{7-14} were found to be derived from peptide bond hydrolysis between amino acids Trp and Ala and between Ala and Val and within the C-terminal amide by high-resolution mass spectrometry coupled with HPLC (LC−MS).\textsuperscript{44} Nevertheless, in vitro study does not necessarily represent the situation encountered by intravenously administered radiopeptides in vivo. Indeed, using in vivo mouse plasma metabolized fragment of \textsuperscript{177}Lu−AMBA, the weak sites were revealed within the backbone of BBN\textsubscript{7-14} between amino acids Gln and Trp, Trp and Ala, and His and Leu, as well as the terminal amide of \textsuperscript{177}Lu−AMBA.\textsuperscript{45} It has been proposed and confirmed that neutral endopeptidase (NEP) acts as the major protease in the degradation of bombesin-like radiopeptides in vivo and that the co-injection of NEP inhibitors could enhance stability and tumor uptake of those radiopeptides.\textsuperscript{45−47}

It is worth pointing out that a lack of stability is not an inherent issue for all GRPR agonists. Through structural interventions including peptide chain-length modification, amino acid substitutions, application of an amide-to-triazole replacement strategy, or the introduction of different lengths of spacer bridging the chelator to the peptide receptor-recognition site, the biological profiles (especially of radioligand pharmacokinetics in vivo) could be significantly improved.\textsuperscript{45,48−50} The major hindrance of GRPR agonists is the possible biological effect induced upon receptor binding when a large amount of the agonists is administered for therapeutic purpose. A more-stable GRPR agonist may be still meaningful as an imaging probe.

## CONCLUSIONS

The antagonist-based probe \textsuperscript{68}Ga−NOTA−PEG\textsubscript{3}−RM26 showed higher tumor uptake with lower background in the PC-3 tumor bearing mouse model at 1 h post-injection and displayed more-favorable in vivo pharmacokinetic properties as well as metabolic stabilities. \textsuperscript{68}Ga−NOTA−PEG\textsubscript{3}−RM26 is, therefore, a more-promising candidate for clinical translation of PET imaging for PCa compared to the agonist \textsuperscript{68}Ga−NOTA−Aca−BBN\textsubscript{7-14}.

## MATERIALS AND METHODS

### Chemistry

Aminocaproic acid (Aca)−BBN\textsubscript{7-14} and RM26 were synthesized using solid-phase Fmoc chemistry by Peptides International Inc. and CSBio. 1,4,7-Triazacyclononane-1,4,7-trietic acid N-hydroxysuccinimide (NOTA−NHS) ester was purchased from CheMatech (Dijon, France). All other chemicals were obtained from Sigma-Aldrich. NOTA−Aca−BBN\textsubscript{7-14} and NOTA−PEG\textsubscript{3}−RM26 were prepared according to a procedure published previously.\textsuperscript{37}

---

**Figure 7.** In vivo metabolic stabilities of \textsuperscript{68}Ga−NOTA−Aca−BBN\textsubscript{7-14} and \textsuperscript{68}Ga−NOTA−PEG\textsubscript{3}−RM26, respectively, in serum at 5 min after injection and urine and tumor at 30 min after injection. (A) Stability of \textsuperscript{68}Ga−NOTA−Aca−BBN\textsubscript{7-14} in serum at 5 min post-injection. (B) Stability of \textsuperscript{68}Ga−NOTA−PEG\textsubscript{3}−RM26 in serum at 5 min post-injection. (C) Stability of \textsuperscript{68}Ga−NOTA−Aca−BBN\textsubscript{7-14} in tumor at 30 min post-injection. (D) Stability of \textsuperscript{68}Ga−NOTA−PEG\textsubscript{3}−RM26 in tumor at 30 min post-injection. (E) Stability of \textsuperscript{68}Ga−NOTA−Aca−BBN\textsubscript{7-14} in urine at 30 min post-injection. (F) Stability of \textsuperscript{68}Ga−NOTA−PEG\textsubscript{3}−RM26 in urine at 30 min post-injection.
Briefly, PC-3 cells were freshly harvested and seeded in 96-well plates at 10^4 cells/50 μL per well in RPMI 1640 binding buffer (with 0.1% bovine serum albumin, serum free). ^{125}I-[Tyr4]BBN was diluted in binding buffer with a specific activity of 2.2 KBq/50 μL. The cells and diluted ^{125}I-[Tyr4]BBN were then incubated, respectively, with increasing concentrations of BBN_7-14, PEG_3-RM26, NOTA-Aca-BBN_7-14 and NOTA-PEG_3-RM26 ranging from 0 to 2000 nmol/L in 37 °C up to 60 min. The IC_{50} values were determined by nonlinear regression analysis using Graph-Pad Prism (GraphPad Software, Inc.). Experiments were performed in triplicate.

**Cell Uptake and Internalization Studies.** The uptake and internalization of ^{68}Ga-NOTA–Aca–BBN_7-14 and ^{68}Ga-NOTA–PEG_3–RM26 in PC-3 cells were examined according to the following procedures, respectively. For the cell uptake experiment, PC-3 cells were seeded in 24-well plates at a density of 10^5 cells per well 24 h before the assay. The medium was removed, and the cells were rinsed twice with PBS. Then, 7.4 KBq per well of tracers (with the corresponding specific activities of 40.0 MBq/nmol and 53.3 MBq/nmol for ^{68}Ga-NOTA–Aca–BBN_7-14 and ^{68}Ga-NOTA–PEG_3–RM26) were added in 0.5 mL of serum-free media (SFDM). The cells were incubated at 37 °C for 5, 15, 30, and 60 min. At each indicated time point, the medium was removed, and cells were rinsed twice with cold PBS (1 mL) and lysed by the addition of 0.2 mL of 0.1 M NaOH. The cell lysate was collected for γ-counting. For internalization study, after the removal of the medium at the same indicated time point as the cell uptake study, the cells were incubated for 1 min with 0.5 mL of acid buffer (50 mM glycine and 100 mM NaCl at pH 2.8). Next, the acid buffer was removed, and the cells were washed twice with 1 mL of PBS, followed by addition of 0.2 mL of 0.1 M NaOH.

Cell lysate was collected, and the radioactivity was measured by a γ-counter. The cell uptake and internalization values were normalized to the amount of added radioactivity. Each experiment was performed in triplicate.

**Cell Efflux Studies.** For a cell-efflux study of ^{68}Ga-NOTA–Aca–BBN_7-14 and ^{68}Ga-NOTA–PEG_3–RM26 (25.2 MBq/nmol), 7.4 KBq per well of tracers were added to PC-3 cells in a 24-well plate and incubated for 1 h at 37 °C. Next, cells were washed twice with cold PBS and incubated with SFDM for 5, 15, 30, and 60 min. After being washed twice with PBS, cells were harvested by the addition of 0.2 mL of 0.1 mol/L NaOH. Cell lysate was collected and the radioactivity measured by a γ-counter. Efflux values were calculated by subtracting retention at different time points from 0 min retention and normalized by dividing the total counts at 0 min.

**PET of Tumor-Bearing Mice.** PET scans were obtained using an Inveon small animal PET scanner (Siemens Medical Solutions). Under isoflurane anesthesia, 5 min of static PET scanning was performed at 15, 30, and 60 min after the PC-3 tumor-bearing mice were each intravenously injected with 3.7 MBq of ^{68}Ga-NOTA–Aca–BBN_7-14 (28.2 MBq/nmol) and ^{68}Ga-NOTA–PEG_3–RM26 (32.6 MBq/nmol) in a volume of 100 μL of PBS. The PET images were reconstructed using 3-dimensional ordered-subsets expectation maximum (3D OSEM) followed by maximum a posteriori (MAP) algorithm with a smoothing parameter (OSEM-3D-MAP) of 0.1. For each scan, regions of interest (ROIs) were drawn over the tumor on whole-body decay-corrected coronal images using vendor software (ASI Pro S.2.4.0; Siemens Medical Solutions). The radioactivity accu-
mulation within the tumor was calculated from mean pixel values of the multiple ROI volumes. These values were converted to MBq/mL and then further divided by the administered activity to obtain an image-ROI-derived %ID/g value (assuming a tissue density of 1 g/mL). No correction was applied in this study.

**Biodistribution of** $^{68}$Ga–NOTA–Aca–BBN$_{7-14}$ and $^{68}$Ga–NOTA–PEG$_3$–RM26. Each mouse was intravenously injected with 3.7 MBq of $^{68}$Ga–NOTA–Aca–BBN$_{7-14}$ (28.2 MBq/nmol) ($n = 4$) or $^{68}$Ga–NOTA–PEG$_3$–RM26 (32.6 MBq/nmol) ($n = 3$) in a volume of 100 μL of PBS. At 1 h post-injection, the mice were sacrificed, and blood, heart, liver, kidneys, spleen, bone, muscle, tumor, intestine, pancreas, and lung tissues were collected. The organs were wet-weighed, and the radioactivity was assayed using a γ-counter.

**In Vivo Stability of** $^{68}$Ga–NOTA–Aca–BBN$_{7-14}$ and $^{68}$Ga–NOTA–PEG$_3$–RM26. For serum metabolic stability studies, each healthy Balb/c mouse was injected intravenously with 37 MBq of $^{68}$Ga–NOTA–Aca–BBN$_{7-14}$ (34.9 MBq/nmol) or $^{68}$Ga–NOTA–PEG$_3$–RM26 (46.8 MBq/nmol). At 5 min after injection, the mice were anesthetized, and 100 μL of blood was collected. The blood sample was immediately centrifuged at 13 200 rpm for 5 min. A total of 25 μL of the supernatant was removed and mixed with an equal volume of acetonitrile, with centrifugation at 6000 rpm for 10 min. Next, the extracted solution was injected into an HPLC device for analysis. For urine analysis, the urine was collected at 30 min post-injection, and then 25 μL of the urine was mixed with an equal volume of acetonitrile and centrifuged at 13 200 rpm for 5 min. The supernatant was removed and subjected to HPLC analysis.

For tumor metabolism analysis, a pair of PC-3 tumor bearing mice were injected with 37 MBq of each tracer (with the specific activities of 32.9 and 31.6 MBq/nmol for $^{68}$Ga–NOTA–Aca–BBN$_{7-14}$ and $^{68}$Ga–NOTA–PEG$_3$–RM26, respectively). At 30 min after injection, the mice were sacrificed under anesthesia, and the tumors were removed and weighed. With an equal weight of acetonitrile, the tumor was homogenized on ice and centrifuged at 13 200 rpm for 5 min. A total of 50 μL of the supernatant was removed for HPLC analysis.

The radioactivity of in vivo collected blood, urine, and tumor samples was measured with a γ-counter each time before and after the samples were homogenized or centrifuged to calculate the extraction efficiency. All samples were collected in pre-chilled vials, and all further manipulations were conducted on ice or at 4 °C for centrifugation to prevent further degradation during sample workup.

**Statistical Analysis.** All quantitative data are presented as mean ± 5D. Mean values were compared using one-way ANOVA and the Student t test. P values of <0.05 were considered statistically significant.

**ACKNOWLEDGMENTS**

This work was supported by the National Natural Science Foundation of China (grant nos. 81671718 and 81271600), Natural Science Foundation of Hubei Province of China (grant no. 2016CFB687), and the Intramural Research Program of the National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health. S.C. is a Ph.D. candidate of Tongji Medical College, Huazhong University of Science and Technology, and is partially funded by the China Scholarship Council (CSC) as a visiting student of NIH.

**REFERENCES**

(1) Siegel, R. L., Miller, K. D., and Jemal, A. (2017) Cancer Statistics, 2017. Ca-Cancer J. Clin. 67, 7–30.

(2) Mottet, N., Bellmunt, J., Bolla, M., Briers, E., Cumberbatch, M. G., De Santis, M., Fossati, N., Gross, T., Henry, A. M., Joniau, S., et al. (2017) EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur. Urol. 71, 618–629.

(3) Schuster, D. M., Nanni, C., and Fanti, S. (2016) PET Tracers Beyond FDG in Prostate Cancer. Semin. Nucl. Med. 46, 507–521.

(4) Barentsz, J. O., Richenberg, J., Clements, R., Choyke, P., Verma, S., Villeirs, G., Rouviere, O., Logager, V., and Futterer, J. J. (2012) ESUR prostate MR guidelines 2012. Eur. Radiol. 22, 746–757.

(5) Verma, S., Rajesh, A., Futterer, J. J., Turkbey, B., Scheenen, T. W., Pang, Y., Choyke, P. L., and Kurbhanewicz, J. (2010) Prostate MRI and 3D MR Spectroscopy: How We Do It. AJR. Am. J. Roentgenol. 194, 1414–1426.

(6) Murphy, G., Haider, M., Ghai, S., and Sreeharsha, B. (2013) The Expanding Role of MRI in Prostate Cancer. AJR. Am. J. Roentgenol. 201, 1229–1238.

(7) Woo, S., Suh, C. H., Kim, S. Y., Cho, J. Y., and Kim, S. H. (2017) Diagnostic Performance of Prostate Imaging Reporting and Data System Version 2 for Detection of Prostate Cancer: A Systematic Review and Diagnostic Meta-analysis. Eur. Urol. 72, 177–188.

(8) Schoder, H., Herrmann, K., Gonen, M., Hricak, H., Eberhard, S., Scardino, P., Scher, H. I., and Larson, S. M. (2005) 2-[¹⁸F]Fluoro-2-deoxyglucose Positron Emission Tomography for the Detection of Disease in Patients with Prostate-Specific Antigen Relapse After Radical Prostatectomy. Clin. Cancer Res 11, 4761–4769.

(9) Wilmmer, A. G., Burger, I. A., Sala, E., Hricak, H., Weber, W. A., and Vargas, H. A. (2016) Molecular Imaging of Prostate Cancer. Radiographics 36, 142–159.

(10) Schuster, D. M., Nanni, C., and Fanti, S. (2016) Evaluation of Prostate Cancer with Radiolabeled Amino Acid Analogs. J. Nucl. Med. 57, 615–665.

(11) Jadvar, H. (2011) Prostate Cancer: PET with ¹⁸F-FDG, ¹⁸F- or ¹⁴C-acetate, and ¹⁸F- or ¹⁴C-choline. J. Nucl. Med. 52, 81–89.

(12) Schwarzenbock, S. M., Rauscher, L., Bluemel, C., Fendler, W. P., Rowe, S. P., Pomper, M. G., Ashar-Oromieh, A., Herrmann, K., and Eiber, M. (2017) PSMA Ligands for PET-Imaging of Prostate Cancer. J. Nucl. Med. 58, 1545–1552.

(13) Ceci, F., Herrmann, K., Hadascal, B., Castellucci, P., and Fanti, S. (2017) Therapy Assessment in Prostate Cancer Using Choline and PSMA PET/CT. Eur. J. Nucl. Med. Mol. Imaging 44 (1), 78–83.

(14) Bach-Gansmo, T., Nanni, C., Nieh, P. T., Zanoni, L., Bopsrud, T. V., Sletten, H., Korsan, K. A., Kieboom, J., Tade, F. I., Odewole, O., et al. (2017) Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine (¹⁸F) Positron Emission Tomography for the Detection of Prostate Cancer with Radiolabeled Amino Acid Analogs. AJR, Am. J. Roentgenol. 194, 751–757.

(15) Guo, M., Qu, X., and Qin, X. Q. (2015) Bombesin-Like Peptides and Their Receptors: Recent Findings in Pharmacology and Physiology. Curr. Opin. Endocrinol. Diabetes Obes. 22, 3–8.

(16) Patel, O., Shulkes, A., and Baldwin, G. S. (2006) Gastrin-Releasing Peptide and Cancer. Biochem. Biophys. Acta, Rev. Cancer 1766, 23–41.

**AUTHOR INFORMATION**

Corresponding Authors
*E-mail: evazhu@vip.sina.com.
*E-mail: niug@mail.nih.gov.
*E-mail: shawn.chen@nih.gov.

ORCID®
Xiaoyuan Chen: 0000-0002-9622-0870

Notes
The authors declare no competing financial interest.
(17) Morgat, C., MacGrogan, G., Brouste, V., Velasco, V., Sevenet, N., Bonnefoi, H., Fernandez, P., Debled, M., and Hindle, E. (2017) Expression of Gastrin-Releasing Peptide Receptor (GRPR) in Breast Cancer and its Association with Pathologic, Biological and Clinical Parameters: A Study of 1432 Primary Tumors. J. Nucl. Med. 58, 1401–1407.

(18) Sancho, V., Di Florio, A., Moody, T. W., and Jensen, R. T. (2011) Bombesin Receptor-Mediated Imaging and Cytotoxicity: Review and Current Status. Curr. Drug Delivery 8, 79–134.

(19) Ferreira, C. A., Fuscaldi, L. L., Townsend, D. M., Rubello, D., and Barros, A. L. B. (2017) Radiolabeled Bombesin Derivatives for Preclinical Oncological Imaging. Biomed. Pharmacother. 87, 58–72.

(20) Smith, C. J., Gali, H., Sieckman, G. L., Hayes, D. L., Owen, N. K., Mazuru, D. G., Volkert, W. A., and Hoffman, T. J. (2003) Radiochemical Investigations of \( \text{\textsuperscript{177}} \text{Lu-DOTA-8-Aoc-BBN(7–14)NH\textsubscript{2}} \) An In Vitro/In Vivo Assessment of the Targeting Ability of This New Radiopharmaceutical for PC-3 Human Prostate Cancer Cells. Nucl. Med. Biol. 30, 101–109.

(21) Smith, C. J., Gali, H., Sieckman, G. L., Higinbotham, C., Volkert, W. A., and Hoffman, T. J. (2003) Radiochemical Investigations of \( \text{\textsuperscript{99m}Te-N,S-X-BBN(7–14)NH\textsubscript{2}} \): An In Vitro/In Vivo Structure-Activity Relationship Study Where \( X = 0-, 3-, 5-, 8-, 11\)-Carbon Tethering Moieties. Bioconjugate Chem. 14, 93–102.

(22) Prasapanich, A. F., Nanda, P. K., Rold, T. L., Ma, L., Lewis, M. R., Garrison, J. C., Hoffman, T. J., Sieckman, G. L., Figueroa, S. D., and Smith, C. J. (2007) \( \text{\textsuperscript{68}Ga-NOTA-S-BBN(7–14)NH\textsubscript{2}} \) Targeting Vector for Positron-Emission Tomography Imaging of Gastrin-Releasing Peptide Receptor-Expressing Tissues. Proc. Natl. Acad. Sci. U. S. A. 104, 12462–12467.

(23) Zhang, J. Li, D., Lang, L., Zhu, Z., Wang, L., Wu, P., Niu, G., Li, F., and Chen, X. (2016) \( \text{\textsuperscript{68}Ga-NOTA-Aca-BBN(7–14)} \) PET/CT in Healthy Volunteers and Glioma Patients. J. Nucl. Med. 57, 9–14.

(24) Minamimoto, R., Hancock, S., Schneider, B., Chin, F. T., Jamali, M., Loening, A., Vasanawala, S., Gambhir, S. S., and Iagaru, A. (2016) Selection of Optimal Chelator Improves the Contrast of Radiolabeled Bombesin Derivatives for Gastrin-Releasing Peptide Receptor Targeting. Curr. Pharm. Des. 19, 3329–3341.

(25) Liu, Z., Niu, G., Wang, F., and Chen, X. (2009) \( \text{\textsuperscript{66}Ga-Labeled NOTA-RGD-BBN} \) Peptide for Dual Integrin and GRPR-Targeted Tumor Imaging. Eur. J. Nucl. Med. Mol. Imaging 36, 1483–1494.

(26) Lin, M., Celar, M. J., and Lapi, S. E. (2013) Effects of Chelator Modifications on \( \text{\textsuperscript{68}Ga-Labeled [Tyr\textsuperscript{3}]Octreotide Conjugates} \). Mol. Imaging Biol. 15, 606–613.

(27) Guo, H., Yang, J., Gallazzi, F., and Miao, Y. (2011) Effects of the Amino Linkers on the Melanoma-Targeting and Pharmacokinetic Properties of \( \text{\textsuperscript{111}In-Labeled Lactam Bridge-Cyclized Alpha-MSH Peptides} \). J. Nucl. Med. 52, 608–616.

(28) Mansi, B., Wang, X., Forrer, F., Waser, B., Cesaro, R., Graham, B., Brockowski, S., Reubi, J. C., and Maecke, H. R. (2011) Development of a Potent DOTA-Conjugated Bombesin Antagonist for Targeting GRPR-Positive Tumours. Eur. J. Nucl. Med. Mol. Imaging 38, 97–107.

(29) Chen, J., Linder, K. E., Cagnolini, A., Metcalfe, E., Raju, N., Tweedle, M. F., and Swenson, R. E. (2008) Synthesis, Stabilization and Formulation of \( \text{\textsuperscript{117}Lu-AMBA} \), a Systemic Radiotherapeutic Agent for Gastrin Releasing Peptide Receptor Positive Tumours. Appl. Radiat. Isot. 66, 497–505.

(30) Cagnolini, A., Chen, J., Ramos, K., Skedzielewski, T. M., Lantry, L. E., Nunn, A. D., Swenson, R. E., and Linder, K. E. (2010) Automated Synthesis, Characterization and Biological Evaluation of \( \text{\textsuperscript{66}Ga-GA-AMBA and [\textsuperscript{68}Ga]-GA-AMBA} \), Appl. Radiat. Isot. 68, 2285–2292.

(31) Linder, K. E., Metcalfe, E., Arunachalam, T., Chen, J., Eaton, S. M., Feng, W., Fan, H., Raju, N., Cagnolini, A., Lantry, L. E., et al. (2009) In Vitro and In Vivo Metabolism of Lu-AMBA, a GRP-Receptor Binding Compound, and the Synthesis and Characterization of Its Metabolites. Bioconjugate Chem. 20, 1171–1178.

(32) Ma, Y., Yang, M., Gao, H., Niu, G., Yan, Y., Lang, L., Kiesewetter, D. O., and Chen, X. (2012) Evaluation of Fluorine-Labeled Gastrin-Releasing Peptide Receptor (GRPR) Agonists and Antagonists by LC/MS. Aca. Radio. Phys. 52, 57–62.

(33) Varathes, Z., Mitran, B., Rosenstrom, U., Velikyan, I., Rosestedt, M., Lindeberg, G., Sorensen, J., Larhed, M., Tolmachev, V., and Orlova, A. (2013) Synthesis and Characterization of a High-Affinity NOTA-Conjugated Bombesin Antagonist for GRPR-Targeted Tumor Imaging. Bioconjugate Chem. 24, 1144–1153.

(34) Varathes, Z., Mitran, B., Rosenstrom, U., Velikyan, I., Rosestedt, M., Lindeberg, G., Sorensen, J., Larhed, M., Tolmachev, V., and Orlova, A. (2015) The Effect of Macrocyclic Chelators on the Targeting Properties of the \( \text{\textsuperscript{68}Ga-Labeled Gastrin Releasing Peptide Receptor Antagonist PEG2-RM26} \). Nucl. Med. Biol. 42, 446–454.

(35) Mitran, B., Varathes, Z., Selvaraju, R. K., Lindeberg, G., Sorensen, J., Larhed, M., Tolmachev, V., Rosenstrom, U., and Orlova, A. (2016) Selection of Optimal Chelator Improves the Contrast of GRPR Imaging Using Bombesin Analogue RM26. Int. J. Oncol. 48, 2124–2134.

(36) Niu, G., Zhang, H., Waser, B., Cesaro, R., Wild, D., Wang, X., Erchegyi, J., Rivier, J., Macke, H. R., and Reubi, J. C. (2006) Radiolabeled Somatostatin Receptor Antagonists Are Preferable to Agonists for In Vivo Gastrin Receptor Targeting of Tumors. Proc. Natl. Acad. Sci. U. S. A. 103, 16436–16441.

(37) Cesaro, R., Maina, T., Nock, B., Nikolopoulos, A., Charalambidis, D., Piccard, V., and Reubi, J. C. (2008) Bombesin Receptor Antagonists May Be Preferable to Agonists for Tumor Targeting. J. Nucl. Med. 49, 318–326.
Regulates the Growth of Small Cell Carcinomas of the Lung. *Proc. Natl. Acad. Sci. U. S. A.* 88, 10662–10666.

(48) Fani, M., and Maecke, H. R. (2012) Radiopharmaceutical Development of Radiolabelled Peptides. *Eur. J. Nucl. Med. Mol. Imaging* 39 (1), 11–30.

(49) Mascarin, A., Valverde, I. E., Vomstein, S., and Mindt, T. L. (2015) 1,2,3-Triazole Stabilized Neurotensin-Based Radiopeptidomimetics for Improved Tumor Targeting. *Bioconjugate Chem.* 26, 2143–2152.

(50) Valverde, I. E., Vomstein, S., and Mindt, T. L. (2016) Toward the Optimization of Bombesin-Based Radiotracers for Tumor Targeting. *J. Med. Chem.* 59, 3867–3877.

(51) Lang, L., Ma, Y., Kiesewetter, D. O., and Chen, X. (2014) Stability Analysis of Glutamic Acid Linked Peptides Coupled to NOTA Through Different Chemical Linkages. *Mol. Pharmaceutics* 11, 3867–3874.

(52) Chen, X., Park, R., Hou, Y., Tohme, M., Shahinian, A. H., Bading, J. R., and Conti, P. S. (2004) MicroPET and Autoradiographic Imaging of GRP Receptor Expression with $^{64}$Cu-DOTA-[Lys]$^3$-Bombesin in Human Prostate Adenocarcinoma Xenografts. *J. Nucl. Med.* 45, 1390–1397.